Featured Technology: Recombinant Thrombin for Surgical Hemostasis
ثبت نشده
چکیده
One of the underlying challenges in any surgical procedure is to maintain or regain hemostasis. Classic surgical training reinforces the axiom that careful attention to surgical hemostasis can help reduce blood loss and transfusion and ultimately improve patient outcomes. There are many challenges to hemostasis in the vascular surgery population due to advanced age at presentation, prior procedures/medical history, and the use of prophylactic anticoagulant and antiplatelet medications. Fortunately, advances in preoperative assessment, perioperative care, and topical hemostatic agents have provided new tools for managing hemostasis in surgery. This article highlights a new hemostatic agent developed through the use of recombinant DNA (rDNA) technology.
منابع مشابه
Recombinant Factors for Hemostasis
Thrombin is the key serine protease in hemostasis because it is responsible for activating both procoagulant proteins critical for creating fibrin clots and anticoagulant proteins needed to return the system to balance. Prothrombin is converted to thrombin in primary hemostasis by activated Factor X (FXa) attached to the phospholipid membrane and secondary hemostasis by the prothrombinase compl...
متن کاملThe modified recombinant proinsulin: a simple and efficient route to produce insulin glargine in E. coli
Background: Recombinant insulin glargine, a long-acting analogue of insulin, is expressed as proinsulin in host cell and after purification and refolding steps cleaved to active insulin by enzymatic digestion using trypsin and carboxypeptidase B. Since the proinsulin's B and C chains have several internal arginine and lysine residues, a number of impurities are generated following treatment wit...
متن کاملSafety and immunogenicity of recombinant human thrombin: a pooled analysis of results from 10 clinical trials.
STUDY OBJECTIVE To evaluate the safety and immunogenicity of recombinant human thrombin (rThrombin), an active topical stand-alone hemostatic agent. DESIGN Analysis of pooled data from 10 rThrombin clinical trials. PATIENTS A total of 644 adult and pediatric patients treated with rThrombin; 609 patients were included in the immunogenicity analysis. MEASUREMENTS AND MAIN RESULTS In all stu...
متن کاملThrombography reveals thrombin generation potential continues to deteriorate following cardiopulmonary bypass surgery despite adequate hemostasis.
The intrinsic and extrinsic activation pathways of the hemostatic system converge when prothrombin is converted to thrombin. The ability to generate an adequate thrombin burst is the most central aspect of the coagulation cascade. The thrombin-generating potential in patients following cardiopulmonary bypass (CPB) may be indicative of their hemostatic status. In this report, thrombography, a un...
متن کاملEvaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)
Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...
متن کامل